Halbert Hargrove Global Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$964 Buy
+2
New +$886 ﹤0.01% 447
2025
Q4
Sell
-13
Closed -$5.09K 736
2025
Q3
$5.09K Buy
+13
New +$5.43K ﹤0.01% 415
2025
Q2
Sell
-5
Closed -$2.26K 651
2025
Q1
$2.26K Buy
+5
New +$2.33K ﹤0.01% 394

Other funds holding VRTX

Halbert Hargrove Global Advisors's VRTX Position: Q2 2026 in Review

Halbert Hargrove Global Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 2 shares worth $964. The stake represents ﹤0.01% of the portfolio and ranks #447 among its holdings. This is a return to the name: Halbert Hargrove Global Advisors previously reported a position in VRTX as recently as Q3 2025.

Halbert Hargrove Global Advisors first reported a position in VRTX in Q1 2025 and has held it in 3 quarters since. The position peaked at $5.09K in Q3 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Halbert Hargrove Global Advisors held 2 shares of Vertex Pharmaceuticals worth $964 as of Q2 2026.
  • Vertex Pharmaceuticals was a new Halbert Hargrove Global Advisors position in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Halbert Hargrove Global Advisors's portfolio in Q2 2026, its #447 holding.
  • Halbert Hargrove Global Advisors first reported a position in Vertex Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
  • Halbert Hargrove Global Advisors's Vertex Pharmaceuticals position peaked at $5.09K in Q3 2025.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Halbert Hargrove Global Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.